The most prevalent retinal diseases include dry and wet age-related macular degeneration, diabetic macular oedema, diabetic retinopathy, retinal vein occlusion, cystoid macular oedema and uveitis. Some of these conditions are chronic or recurring and can present as early as age 40.
Our drug administration technology enables routine administration to deliver drugs to specific back-of-eye tissues, including the suprachoroidal, sub-retinal and other small spaces. Our approach improves both therapeutic benefits and safety.
Our drug formulations are designed to suit the unique ocular environments into which they are delivered, resulting in optimised pharmacokinetics and pharmacodynamics as well clinical effects lasting up to twelve months in duration.
Oxular’s development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema and aged related macular degeneration, plus programs for rare and orphan conditions, including ocular cancers and delivery of gene therapy.
